Timothy C. Atkins is a partner in the Commercial Department in the Berwyn office of Pepper Hamilton LLP. He concentrates his practice in the representation of pharmaceutical, biotechnology, computer and other high technology companies with a particular emphasis on corporate transactions and intellectual property transactions. Mr. Atkins is chair of the firm’s Technology Committee. He also is a member of the firm’s Italian Desk.
Mr. Atkins counsels a wide range of businesses, from startups and smaller, venture capital-backed businesses to publicly traded, global businesses in the biotechnology and pharmaceutical sectors on corporate transactions, mergers and acquisitions and financing matters, as well as the acquisition, protection, commercialization and disposition of intellectual property assets. He also has represented various universities in technology transfer transactions, many of which have involved licensing of pharmaceutical compounds and related patents and equity transactions.
Representative transactions in which Mr. Atkins has participated include:
- $50 million Series B financing of a development stage pharmaceutical company
- representation of a publicly traded biotechnology and diagnostics company in the global commercialization of a patented technology platform for use in various diagnostic applications including structuring and negotiating research, development and supply agreements for instrumentation, assays and related supplies and the cross-licensing of various technologies
- out-licensing of a pharmaceutical compound candidate directed to the treatment of heart disease and related intellectual property by a large pharmaceutical company to a venture capital-backed pharmaceutical company
- out-licensing of a peptide directed to the treatment of diabetes by a venture capital-backed company to a global pharmaceutical company
- representation of a venture capital-backed company in a license and collaboration transaction involving its drug discovery platform
- worldwide out-licensing of an approved product used in the palliative treatment of prostate cancer
- an acquisition of an off-the-market pharmaceutical product line including all related assets
- representation of a specialty pharmaceutical company in connection with all aspects of its commercialization activities including out-licensing, in-licensing of a drug candidate and various vendor contracts including supply and quality agreements
- representation of several major universities in the structuring and negotiation of technology transfer transactions including sponsored research agreements, materials transfer and evaluation agreements, license agreements and equity-based technology transfers
- representation of a publicly traded pharmaceutical company in a product development transaction, international licensing arrangements and strategic alliances
- representation of a biotechnology company in a collaboration arrangement and related licensing arrangements with a government-funded research institution
- representation of a database company in the licensing of its absorption, distribution, metabolism and excretion database to pharmaceutical companies
- representation of multiple pharmaceutical companies in connection with pre-clinical and clinical development activities including services agreements with CROs and supporting vendors, clinical study agreements, laboratory services agreements and CRADAs
- multiple development, license, service and sale agreements governing the development, use, supply and commercialization of high technology assets such as software, databases and hardware
- a French software company on the formation of its U.S. affiliate company and licensing of drug discovery software to U.S. pharmaceutical companies
- a pharmaceutical company in the acquisition of mission critical research software
- representation of selling shareholders in $200 million leveraged buyout by management
- representation of a private equity fund in an acquisition of a call center business and aircraft charter services businesses
- negotiation and documentation of senior debt, mezzanine debt and preferred equity investments
- various companies and individuals in connection with mergers and acquisitions, including asset purchase and stock purchase transactions, cash-out mergers and stock-for-stock mergers.
Mr. Atkins is a member of several academic and trade organizations including Phi Kappa Phi and the Computer Law Association.
Mr. Atkins is a member of the Chester County and American Bar Associations.